S&P 500   4,592.24 (+0.56%)
DOW   35,876.60 (+0.38%)
QQQ   381.84 (+1.03%)
AAPL   149.91 (+0.85%)
MSFT   312.07 (+1.28%)
FB   321.90 (-2.07%)
GOOGL   2,781.35 (+1.18%)
TSLA   1,049.74 (+2.43%)
AMZN   3,406.26 (+2.59%)
NVDA   249.30 (+7.61%)
BABA   171.14 (-2.86%)
NIO   41.40 (+0.31%)
CGC   13.39 (-1.33%)
GE   107.95 (+2.52%)
AMD   125.07 (+2.21%)
MU   69.19 (+0.63%)
T   25.51 (-0.51%)
F   15.90 (-0.63%)
ACB   7.04 (-1.95%)
DIS   172.43 (+0.24%)
PFE   43.24 (+0.21%)
BA   212.45 (-0.20%)
AMC   36.41 (-1.14%)
S&P 500   4,592.24 (+0.56%)
DOW   35,876.60 (+0.38%)
QQQ   381.84 (+1.03%)
AAPL   149.91 (+0.85%)
MSFT   312.07 (+1.28%)
FB   321.90 (-2.07%)
GOOGL   2,781.35 (+1.18%)
TSLA   1,049.74 (+2.43%)
AMZN   3,406.26 (+2.59%)
NVDA   249.30 (+7.61%)
BABA   171.14 (-2.86%)
NIO   41.40 (+0.31%)
CGC   13.39 (-1.33%)
GE   107.95 (+2.52%)
AMD   125.07 (+2.21%)
MU   69.19 (+0.63%)
T   25.51 (-0.51%)
F   15.90 (-0.63%)
ACB   7.04 (-1.95%)
DIS   172.43 (+0.24%)
PFE   43.24 (+0.21%)
BA   212.45 (-0.20%)
AMC   36.41 (-1.14%)
S&P 500   4,592.24 (+0.56%)
DOW   35,876.60 (+0.38%)
QQQ   381.84 (+1.03%)
AAPL   149.91 (+0.85%)
MSFT   312.07 (+1.28%)
FB   321.90 (-2.07%)
GOOGL   2,781.35 (+1.18%)
TSLA   1,049.74 (+2.43%)
AMZN   3,406.26 (+2.59%)
NVDA   249.30 (+7.61%)
BABA   171.14 (-2.86%)
NIO   41.40 (+0.31%)
CGC   13.39 (-1.33%)
GE   107.95 (+2.52%)
AMD   125.07 (+2.21%)
MU   69.19 (+0.63%)
T   25.51 (-0.51%)
F   15.90 (-0.63%)
ACB   7.04 (-1.95%)
DIS   172.43 (+0.24%)
PFE   43.24 (+0.21%)
BA   212.45 (-0.20%)
AMC   36.41 (-1.14%)
S&P 500   4,592.24 (+0.56%)
DOW   35,876.60 (+0.38%)
QQQ   381.84 (+1.03%)
AAPL   149.91 (+0.85%)
MSFT   312.07 (+1.28%)
FB   321.90 (-2.07%)
GOOGL   2,781.35 (+1.18%)
TSLA   1,049.74 (+2.43%)
AMZN   3,406.26 (+2.59%)
NVDA   249.30 (+7.61%)
BABA   171.14 (-2.86%)
NIO   41.40 (+0.31%)
CGC   13.39 (-1.33%)
GE   107.95 (+2.52%)
AMD   125.07 (+2.21%)
MU   69.19 (+0.63%)
T   25.51 (-0.51%)
F   15.90 (-0.63%)
ACB   7.04 (-1.95%)
DIS   172.43 (+0.24%)
PFE   43.24 (+0.21%)
BA   212.45 (-0.20%)
AMC   36.41 (-1.14%)
NASDAQ:APLS

Apellis Pharmaceuticals Stock Forecast, Price & News

$31.95
-0.14 (-0.44 %)
(As of 10/26/2021 11:20 AM ET)
Add
Compare
Today's Range
$31.58
$32.81
50-Day Range
$31.40
$66.39
52-Week Range
$27.50
$73.00
Volume7,167 shs
Average Volume1.08 million shs
Market Capitalization$2.78 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.73
30 days | 90 days | 365 days | Advanced Chart
Receive APLS News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Apellis Pharmaceuticals logo

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLS
Employees
374
Year Founded
N/A

Sales & Book Value

Annual Sales
$250.65 million
Book Value
$2.70 per share

Profitability

Net Income
$-344.87 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$2.78 billion
Next Earnings Date
11/1/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.48 out of 5 stars

Medical Sector

133rd out of 1,360 stocks

Pharmaceutical Preparations Industry

55th out of 667 stocks

Analyst Opinion: 4.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions

Is Apellis Pharmaceuticals a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Apellis Pharmaceuticals stock.
View analyst ratings for Apellis Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Apellis Pharmaceuticals?

Wall Street analysts have given Apellis Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Apellis Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Apellis Pharmaceuticals' next earnings date?

Apellis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Apellis Pharmaceuticals
.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) issued its quarterly earnings data on Sunday, August, 8th. The company reported ($2.72) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.70) by $1.02. The firm had revenue of $0.62 million for the quarter, compared to analyst estimates of $2.26 million.
View Apellis Pharmaceuticals' earnings history
.

How has Apellis Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Apellis Pharmaceuticals' stock was trading at $27.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, APLS stock has increased by 17.3% and is now trading at $31.95.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for APLS?

13 brokers have issued 12 month price targets for Apellis Pharmaceuticals' stock. Their forecasts range from $38.00 to $130.00. On average, they expect Apellis Pharmaceuticals' stock price to reach $73.79 in the next twelve months. This suggests a possible upside of 130.9% from the stock's current price.
View analysts' price targets for Apellis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Apellis Pharmaceuticals' key executives?

Apellis Pharmaceuticals' management team includes the following people:
  • Cedric Francois, President, Chief Executive Officer & Director
  • Timothy Eugene Sullivan, Chief Financial Officer & Treasurer
  • Pascal Deschatelets, Chief Scientific Officer
  • Federico Grossi, Chief Medical Officer (LinkedIn Profile)
  • Nur Nicholson, Chief Technical Operations Officer

What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

6 employees have rated Apellis Pharmaceuticals CEO Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among Apellis Pharmaceuticals' employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (0.32%), Private Advisor Group LLC (0.17%), DekaBank Deutsche Girozentrale (0.03%), Strs Ohio (0.03%), Ipswich Investment Management Co. Inc. (0.03%) and Belvedere Trading LLC (0.02%). Company insiders that own Apellis Pharmaceuticals stock include A Sinclair Dunlop, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Lukas Scheibler, Mark Jeffrey Delong, Nicole D Perry, Pascal Deschatelets and Victoria L Brown.
View institutional ownership trends for Apellis Pharmaceuticals
.

Which major investors are selling Apellis Pharmaceuticals stock?

APLS stock was sold by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include A Sinclair Dunlop, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Lukas Scheibler, Mark Jeffrey Delong, Nicole D Perry, and Pascal Deschatelets.
View insider buying and selling activity for Apellis Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Apellis Pharmaceuticals stock?

APLS stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Private Advisor Group LLC, Belvedere Trading LLC, Strs Ohio, Sippican Capital Advisors, S.A. Mason LLC, Ipswich Investment Management Co. Inc., and Nisa Investment Advisors LLC.
View insider buying and selling activity for Apellis Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $31.95.

How much money does Apellis Pharmaceuticals make?

Apellis Pharmaceuticals has a market capitalization of $2.78 billion and generates $250.65 million in revenue each year. The company earns $-344.87 million in net income (profit) each year or ($4.59) on an earnings per share basis.

How many employees does Apellis Pharmaceuticals have?

Apellis Pharmaceuticals employs 374 workers across the globe.

What is Apellis Pharmaceuticals' official website?

The official website for Apellis Pharmaceuticals is www.apellis.com.

Where are Apellis Pharmaceuticals' headquarters?

Apellis Pharmaceuticals is headquartered at 100 FIFTH AVENUE, WALTHAM MA, 02451.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company can be reached via phone at (617) 977-5700 or via email at [email protected].


This page was last updated on 10/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.